FerrerinCode - Farmacología / Bibliografia

Accesos >

Differences in CYP3A5*3 Genoptype Distribution and Combinations With Other Polymorphisms Between Spaniards and Other Caucasian Populations. Gervasini et al. Ther Drug Monit, Vol 27, December 2005.+info
Drug-metabolizing enzyme: Evidence for clinical utility of pharmacogenomic tests. Anderson et al. Clinical Pharmacology & Therapeutics. Vol 78, No. 6. 2005+info
Pharmacogenomics and Individualized Drug Therapy. Eichelbaum et al. Annu. Rev. Med. 2006. 57:119-37+info
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Magnus Ingelman-Sundberg. Trends in Pharmacological Sciences. Vol. 25 No 4. 2004.+info
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. Pirmohamed et al. BMJ 2004 329(7456):15-9+info

Pharmacogenomics of importance for paclitaxel therapy. Green H. Pharmacogenomics 2008 9(6) 671-674. +info
Pharmacogenomics of tamoxifen and aromatase inhibitors. Ingle. Cancer 2008 Feb 1 (112) 695-699. +info
Tamoxifen pharmacogenomics. The role of CYP 2D6 as a predictor of drug response. Goetz et al. Clin. Pharmacol. Ther. 2008 jan;83 (1): 160-6. +info
Prediction of efficacy and side effects of chemotherapy in colorectal cancer. Stoehlmacher J. Recent Results Cancer Res. 2007; 176: 81-8 +info
Pharmacogenetic approach for cancer treatment-tailored medicine in practice. Hasegawa Y. et al. Ann. NY Acad Sci +info

Clinical guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19. de León et al. Psycosomatics 47:1 Jan-Feb 2006.+info
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Kirrchhainer et al. Acta Psychiatrica Scandinava 2001: 104: 173-192+info
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. Lieberman et al. New England Journal of Medicine. Vol. 353 No 12, 2005.+info
The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Brockmoller et al.+info
Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. Kirchheiner J. et al. J CLlin Psychopharmacol 2004 24(6):647-52 +info

Effect of CYP3A5 Polymorphism on Tacrolimus Metabolic Clearance in vitro. Dai et al. Drug Metabolism and Disposition. The American Society for Pharmacology and Experimental Therapeutics. Vol.34 No 5. 2006. +info
CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients. Kuypers et al. Clinical Pharmacology & Therapeutics. May 2007. +info
The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Zheng et al. Transpl Immunol. 2005 14(1): 37-42 +info
Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an unpdate. Anglicheau et al. Pharmacogenomics 2007 8(7): 835-49 +info
A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. MacPhee et al. Transplantation. +info

Ferrer inCode Diagonal, 549 5ª planta, E-08029 Barcelona - España - Tel.: +34 93 600 37 00 - Fax: +34 93 490 70 78